IV Infuse over 60 min.
Locally advanced NSCLC Patient weighing ≥30 kg 10 mg/kg every 2 wk, or 1,500 mg every 4 wk,
<30 kg 10 mg/kg every 2 wk until disease progression, unacceptable toxicity, or max of 12 mth.
In combination w/ tremelimumab & platinum-based chemotherapy Patient w/ non-squamous or squamous tumor histology weighing ≥30 kg 1,500 mg & 75 mg tremelimumab w/ carboplatin & nab-paclitaxel, or carboplatin or cisplatin & pemetrexed,
<30 kg 20 mg/kg & 1 mg/kg tremelimumab w/ carboplatin & nab-paclitaxel, or carboplatin or cisplatin & pemetrexed. Dosage schedule: Dosing interval of every 3 wk to every 4 wk starting cycle 5. Continue treatment until disease progression or intolerable toxicity. Give remaining cycles of tremelimumab (up to total of 5) every 4 wk after platinum-based chemotherapy phase in combination w/ Imfinzi, if patient receives fewer than 4 cycles of platinum-based chemotherapy.
ES-SCLC Patient weighing ≥30 kg 1,500 mg in combination w/ chemotherapy every 3 wk (21 days) for 4 cycles, followed by 1,500 mg every 4 wk as single agent,
<30 kg 20 mg/kg in combination w/ chemotherapy every 3 wk (21 days) for 4 cycles, followed by 10 mg/kg every 2 wk as single agent until disease progression or unacceptable toxicity.
uHCC Patient weighing ≥30 kg 1,500 mg following single dose of tremelimumab 300 mg at day 1 of cycle 1. Continue 1,500 mg as single agent every 4 wk,
<30 kg 20 mg/kg following single dose of tremelimumab 4 mg/kg at day 1 of cycle 1. Continue 20 mg/kg as single agent every 4 wk until disease progression or unacceptable toxicity.
BTC Patient weighing ≥30 kg 1,500 mg in combination w/ gemcitabine & cisplatin every 3 wk (21 days) for 8 cycles, followed by 1,500 mg every 4 wk as single agent,
<30 kg 20 mg/kg in combination w/ gemcitabine & cisplatin every 3 wk (21 days) for 8 cycles, followed by 20 mg/kg every 4 wk as single agent until disease progression or unacceptable toxicity.
Sign Out
